1. Sign our petition calling on Cochrane to withdraw their review of Exercise Therapy for CFS here.
    Dismiss Notice
  2. Guest, the 'News in Brief' for the week beginning 15th April 2024 is here.
    Dismiss Notice
  3. Welcome! To read the Core Purpose and Values of our forum, click here.
    Dismiss Notice

Distinct CholinomiR Blood Cell Signature as a Potential Modulator of the Cholinergic System in Women with Fibromyalgia, 2022, Christoph Eracher et al

Discussion in ''Conditions related to ME/CFS' news and research' started by Mij, May 28, 2022.

  1. Mij

    Mij Senior Member (Voting Rights)

    Messages:
    8,332
    Abstract

    Fibromyalgia syndrome (FMS) is a heterogeneous chronic pain syndrome characterized by musculoskeletal pain and other key co-morbidities including fatigue and a depressed mood. FMS involves altered functioning of the central and peripheral nervous system (CNS, PNS) and immune system, but the specific molecular pathophysiology remains unclear. Anti-cholinergic treatment is effective in FMS patient subgroups, and cholinergic signaling is a strong modulator of CNS and PNS immune processes. Therefore, we used whole blood small RNA-sequencing of female FMS patients and healthy controls to profile microRNA regulators of cholinergic transcripts (CholinomiRs). We compared microRNA profiles with those from Parkinson’s disease (PD) patients with pain as disease controls.

    We validated the sequencing results with quantitative real-time PCR (qRT-PCR) and identified cholinergic targets. Further, we measured serum cholinesterase activity in FMS patients and healthy controls. Small RNA-sequencing revealed FMS-specific changes in 19 CholinomiRs compared to healthy controls and PD patients. qRT-PCR validated miR-182-5p upregulation, distinguishing FMS patients from healthy controls. mRNA targets of CholinomiRs bone morphogenic protein receptor 2 and interleukin 6 signal transducer were downregulated. Serum acetylcholinesterase levels and cholinesterase activity in FMS patients were unchanged.

    Our findings identified an FMS-specific CholinomiR signature in whole blood, modulating immune-related gene expression.

    https://www.mdpi.com/2073-4409/11/8/1276/htm
     
    Hutan and Peter Trewhitt like this.
  2. shak8

    shak8 Senior Member (Voting Rights)

    Messages:
    2,227
    Location:
    California
    Anti-cholinergic treatment is effective in FMS patient subgroups, and cholinergic signaling is a strong modulator of CNS and PNS immune processes..."

    news to me. Which drug might that be?

    This research (and I have absolutely no competence in assessing it) seems overly speculative and exceedingly complex. There is comparison with Parkinson Disease group. A shot in the dark, worth taking?
     
  3. Mij

    Mij Senior Member (Voting Rights)

    Messages:
    8,332
    Could this be the reason why amitriptyline works well for FMS?
     
  4. Hutan

    Hutan Moderator Staff Member

    Messages:
    26,941
    Location:
    Aotearoa New Zealand
    Another possibility that DecodeME might be able to check for?
    @Simon M, @Andy
     
    shak8 and Lilas like this.

Share This Page